3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Melanoma
5
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Multiple Myeloma
1
Melanoma, Cutaneous Malignant
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
59
Carboplatin
56
Pemetrexed
47
Cisplatin
39
Paclitaxel
24
Nivolumab
23
Docetaxel
21
durvalumab
20
Gemcitabine
15
130-nm albumin-bound paclitaxel
14
osimertinib
13
Cetuximab
12
Specimen Handling
11
Magnetic Resonance Spectroscopy
11
atezolizumab
10
amivantamab
8
Taxes
8
Radiotherapy
8
Radiosurgery
7
Ipilimumab
7
lazertinib
6
alectinib
6
Ramucirumab
6
Observation
6
Bevacizumab
6
cemiplimab
5
Leucovorin
5
Fluorouracil
5
Etoposide
5
Erlotinib Hydrochloride
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
relatlimab
×
30 days
×
Clear all
NCT05176483
2026-05-27
STELLAR-002
Exelixis
Phase 1
Recruiting
1,314 enrolled
NCT06561386
2026-05-20
RELATIVITY1093
Bristol-Myers Squibb
Phase 3
Recruiting
1,000 enrolled